2026年11月4日星期三
M
Hoàn Vũ Thông Giám
Tin nhanh toàn cầu
US experts warm to Japanese nuclear subs as check on China in Asian waters— 日经 Nikkei AsiaDRAM prices double in 2026 as AI focus squeezes PC makers— 日经 Nikkei AsiaJapan weighs standards for self-driving cars without steering wheels— 日经 Nikkei AsiaMitsubishi to sell part of stake in Canada LNG project to Blackstone funds— 日经 Nikkei AsiaJapan's SBI to invest in US digital bank Erebor, eyeing blockchain settlements— 日经 Nikkei AsiaAnthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaUS midterms live: Flooding forces polling sites to relocate— 日经 Nikkei AsiaUS experts warm to Japanese nuclear subs as check on China in Asian waters— 日经 Nikkei AsiaDRAM prices double in 2026 as AI focus squeezes PC makers— 日经 Nikkei AsiaJapan weighs standards for self-driving cars without steering wheels— 日经 Nikkei AsiaMitsubishi to sell part of stake in Canada LNG project to Blackstone funds— 日经 Nikkei AsiaJapan's SBI to invest in US digital bank Erebor, eyeing blockchain settlements— 日经 Nikkei AsiaAnthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaUS midterms live: Flooding forces polling sites to relocate— 日经 Nikkei Asia

Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Nguồn Nature 医学研究7 ngày trước
Tóm tắt nội dung

Trang này chỉ cung cấp tiêu đề và chỉ mục tóm tắt, toàn bộ nội dung và bản quyền đều thuộc về bên phát hành gốc, vui lòng nhấp vào liên kết gốc để đọc.

Đi tới bài gốc
Kênh trực thuộc
Sức khỏe
Khu vực trực thuộc
Góc nhìn toàn cầu
Ngôn ngữ gốc
English
Số mục
health-a90987bb

Comments 0 comments

No comments yet. Be the first.

Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial · Hoàn Vũ Thông Giám